CG Oncology (CGON) Gains from Investment Securities (2023 - 2026)
CG Oncology posted quarterly Gains from Investment Securities of $437361.0 for Q1 2026, up 551.47% year-on-year from $67134.0 in Q1 2025, and up 580.62% on a QoQ basis from -$91000.0 in Q4 2025.
CG Oncology (CGON) has 4 years of Gains from Investment Securities data on file, last reported at $437361.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities rose 551.47% year-over-year to $437361.0; the trailing twelve-month figure through Mar 2026 stood at $437361.0 (up 551.47% YoY), and the FY2025 full-year result was $8.0 million, up 21.05% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $437361.0, up from -$91000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $9.0 million in Q2 2025 and bottomed at -$91000.0 in Q4 2025.
- The 4-year median for Gains from Investment Securities is $326270.0 (2024), against an average of $3.0 million.
- Peak annual rise in Gains from Investment Securities reached 4065.8% in 2025, while the deepest fall reached 101.38% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at $5.5 million in 2023, then grew by 18.83% to $6.6 million in 2024, then tumbled by 101.38% to -$91000.0 in 2025, then soared by 580.62% to $437361.0 in 2026.
- The last three Gains from Investment Securities figures came in at $437361.0 (Q1 2026), -$91000.0 (Q4 2025), and $94624.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | CG Oncology | 5.01 Bn | 5.01 Bn | -1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,361.00 |
| Mar 31, 2026 | 437,361.00 |
| Dec 31, 2025 | -91,000.00 |
| Dec 31, 2025 | -91,000.00 |
| Sep 30, 2025 | 94,624.00 |
| Sep 30, 2025 | 94,624.00 |
| Jun 30, 2025 | 8.96 Mn |
| Jun 30, 2025 | 8.96 Mn |
| Mar 31, 2025 | 67,134.00 |
| Mar 31, 2025 | 67,134.00 |
| Dec 31, 2024 | 6.57 Mn |
| Dec 31, 2024 | 6.57 Mn |
| Sep 30, 2024 | 7.71 Mn |
| Sep 30, 2024 | 7.71 Mn |
| Jun 30, 2024 | 215,179.00 |
| Jun 30, 2024 | 215,179.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 5.53 Mn |
| Dec 31, 2023 | 5.53 Mn |